168 related articles for article (PubMed ID: 34319443)
21. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
[TBL] [Abstract][Full Text] [Related]
22. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
[No Abstract] [Full Text] [Related]
23. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras.
Cavnar MJ; Seier K; Curtin C; Balachandran VP; Coit DG; Yoon SS; Crago AM; Strong VE; Tap WD; Gönen M; Antonescu CR; Brennan MF; Singer S; DeMatteo RP
Ann Surg; 2021 Jan; 273(1):128-138. PubMed ID: 30946076
[TBL] [Abstract][Full Text] [Related]
24. Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
Nishida T; Sato S; Ozaka M; Nakahara Y; Komatsu Y; Kondo M; Cho H; Hirota S; Kagimura T; Kurokawa Y; Kitagawa Y;
Gastric Cancer; 2022 Sep; 25(5):956-965. PubMed ID: 35672526
[TBL] [Abstract][Full Text] [Related]
25. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2012; 17(7):992-7. PubMed ID: 22643537
[TBL] [Abstract][Full Text] [Related]
26. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
27. [Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor].
Lei C; Liu L; Wang Q; Wang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1300-1304. PubMed ID: 27928804
[TBL] [Abstract][Full Text] [Related]
28. KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.
Joensuu H; Wardelmann E; Eriksson M; Reichardt A; Hall KS; Schütte J; Cameron S; Hohenberger P; Sihto H; Jost PJ; Lindner LH; Bauer S; Nilsson B; Kallio R; Pesonen T; Reichardt P
Clin Cancer Res; 2023 Sep; 29(17):3313-3319. PubMed ID: 37014660
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
30. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
Stuart E; Banerjee S; de la Torre J; Wang Y; Scherzer N; Burgoyne AM; Parry L; Fanta PT; Ramamoorthy S; Sicklick JK
J Surg Oncol; 2019 Sep; 120(4):715-721. PubMed ID: 31297829
[TBL] [Abstract][Full Text] [Related]
31. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Guerin A; Sasane M; Gauthier G; Keir CH; Zhdavana M; Wu EQ
J Med Econ; 2015 Mar; 18(3):241-8. PubMed ID: 25422992
[TBL] [Abstract][Full Text] [Related]
32. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
34. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J;
Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
36. Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence.
Ushimaru Y; Takahashi T; Nakajima K; Teranishi R; Nishida T; Hirota S; Motoori M; Omori T; Kawabata R; Nishikawa K; Saito T; Yamashita K; Tanaka K; Makino T; Yamamoto K; Kurokawa Y; Eguchi H; Doki Y
Int J Clin Oncol; 2022 May; 27(5):921-929. PubMed ID: 35152356
[TBL] [Abstract][Full Text] [Related]
37. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.
Conley AP; Guérin A; Sasane M; Gauthier G; Schwiep F; Keir CH; Wu EQ
J Gastrointest Cancer; 2013 Jun; 44(2):190-8. PubMed ID: 23229801
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
